cardiffoncology.com (CRDF) - Gross Profit Margin

Official company branding of Cardiff Oncology, Inc. (CRDF)

High R&D expenses are keeping Cardiff Oncology, Inc. (CRDF) profitability at a preparatory level. The annual gross margin on the GURU.Markets chart demonstrates current dynamics, where -59.00 reflects the latest metric value amid fierce competition among biotech startups for capital attention. Meanwhile, an extensive patent portfolio ensures demand stability, turning targeted molecules into a steady cash generator.

CRDF (cardiffoncology.com) Return on Gross Profit history from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for cardiffoncology.com (CRDF)

- market price and analyst price targets:
Basic company analysis:Cardiff Oncology, Inc. (CRDF)
Manufactured products of Cardiff Oncology, Inc.

For the biopharmaceutical sector, where Cardiff Oncology, Inc. (CRDF) focuses on the development of inhibitors, this metric serves as a gauge of direct cost management efficiency. By analyzing the gross profit margin, an investor can see the remaining revenue after deducting the cost of goods sold, which, combined with the retention of a unique staff of scientists through stock options, confirms the high fundamental value of the company's intellectual capital.